

REFERENCES

1. American Cancer Society. Cancer Facts & Figure 2008. [online]. Available:
<http://www.cancer.org/Research/CancerFactsFigures/cancer-facts-figures-2008>
(23 December 2010)
2. Number and ratio of deaths population per hundred thousand by cause groups and sex: 1999-2004. [online]. Available:
http://service.nso.go.th/nso/data/data23/stat23/toc_4/4.3-2.xls. (25 December 2010)
3. National Statistical Office of Thailand. “Number and ratio of deaths population per hundred thousand by leading cause group and sex in Chiang Mai province: 2002-2003”. [online] Available:
<http://chiangmai.nso.go.th/> (25 December 2010)
4. The Leukemia & Lymphoma Society Fighting Blood cancer. Facts 2010-2011. [online]. Available:
<http://www.lls.org/resourcecenter/freeducationmaterials/generalcancer/facts>
(23 December 2010)
5. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. *Boold*. 1994; 84 : 3071-9.
6. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Chanarat P, Limtrakul P. Curcumin inhibits WT1 gene expression in human leukemic K562 cells. *Acta Pharmacol Sin*. 2006; 27(3):360-6.

7. Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S, Chanarat P. Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. *Arch Pharm Res.* 2006; 29 : 80-7.
8. Anuchapreeda S, Tima S, Duangrat C, Limtrakul P. Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. *Cancer Chemother Pharmacol.* 2008; 62 : 585-94.
9. Duvoix A, Morceau F, Delhalle S, Schmitz M, Schnekenburger M, Galteau MM, *et al.* Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. *Biochem Pharmacol.* 2003; 66 : 1475-83.
10. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. *Biochim Biophys Acta.* 1996; 1317 : 95-100.
11. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, *et al.* Chemopreventive and therapeutic effects of curcumin. *Cancer Lett.* 2005; 223 : 181-90.
12. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, *et al.* Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. *J Nutr.* 2000; 130 : 467S-71S.
13. Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. *Nutr Cancer.* 1992; 17 : 77-83.
14. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. *Carcinogenesis.* 1992; 13 : 2183-6.

15. Nagabhushan M, Bhide SV. Curcumin as an inhibitor of cancer. *J Am Coll Nutr.* 1992; 11 : 192-8.
16. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, *et al.* Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell.* 1990; 60 : 509-20.
17. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. *Nature.* 1990; 343 : 774-8.
18. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, *et al.* The candidate Wilms' tumour gene is involved in genitourinary development. *Nature.* 1990; 346 : 194-7.
19. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ, 3rd, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. *Proc Natl Acad Sci U S A.* 1992; 89 : 10984-8.
20. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, 3rd, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. *Cancer Res.* 1995; 55 : 5386-9.
21. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ, 3rd. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. *J Biol Chem.* 1993; 268 : 21271-5.
22. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ, 3rd, Kim SJ. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. *Mol Endocrinol.* 1994; 8 : 595-602.

23. Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ, 3rd, Sens DA, *et al.* Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. *Proc Natl Acad Sci U S A.* 1993; 90 : 5828-32.
24. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ, 3rd. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. *Science.* 1992; 257 : 674-8.
25. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. *Genes Dev.* 1998; 12 : 3217-25.
26. Larsson SH, Charlier JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, *et al.* Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. *Cell.* 1995; 81 : 391-401.
27. Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND. The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. *Hum Mol Genet.* 2004; 13 : 463-71.
28. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, *et al.* WT-1 is required for early kidney development. *Cell.* 1993; 74 : 679-91.
29. Lee SB, Haber DA. Wilms tumor and the WT1 gene. *Exp Cell Res.* 2001; 264 : 74-99.
30. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. *Gene.* 2001; 273 : 141-61.

31. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. *Exp Hematol.* 1997; 25 : 312-20.
32. Bergmann L, Maurer U, Weidmann E. Wilms tumor gene expression in acute myeloid leukemias. *Leuk Lymphoma.* 1997; 25 : 435-43.
33. Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. *Blood.* 1995; 86 : 4704-6.
34. Hosen N, Shirakata T, Nishida S, Yanagihara M, Tsuboi A, Kawakami M, *et al.* The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. *Leukemia.* 2007; 21 : 1783-91.
35. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, *et al.* Very low frequencies of human normal CD34⁺ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. *Br J Haematol.* 2002; 116 : 409-20.
36. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34⁺ progenitors and downregulated early in the course of differentiation in vitro. *Exp Hematol.* 1997; 25 : 945-50.
37. Menssen HD, Renkl HJ, Entezami M, Thiel E. Wilms' tumor gene expression in human CD34⁺ hematopoietic progenitors during fetal development and early clonogenic growth. *Blood.* 1997; 89 : 3486-7.

38. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, *et al.* Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia*. 1995; 9 : 1060-7.
39. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. *Leukemia*. 1992; 6 : 405-9.
40. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. *Leukemia*. 1993; 7 : 970-7.
41. Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, *et al.* Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. *Blood*. 1996; 88 : 4396-8.
42. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, *et al.* Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. *Int J Cancer*. 2002; 100 : 297-303.
43. Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S, *et al.* Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. *Cancer Sci*. 2003; 94 : 606-11.
44. Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, Koga S, *et al.* Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. *Cancer Sci*. 2003; 94 : 271-6.
45. Seidl C, Siehl J, Ganser A, Hofmann WK, Fischer M, Kirchmaier CM, *et al.* Platelet glycoprotein expression in patients with myelodysplastic syndrome. *Thromb Res*. 2000; 100 : 27-34.

46. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, *et al.* Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. *Jpn J Cancer Res.* 1999; 90 : 194-204.
47. Hubinger G, Schmid M, Linortner S, Manegold A, Bergmann L, Maurer U. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. *Exp Hematol.* 2001; 29 : 1226-35.
48. Li H, Oka Y, Tsuboi A, Yamagami T, Miyazaki T, Yusa S, *et al.* The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. *Int J Hematol.* 2003; 77 : 463-70.
49. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, *et al.* WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. *EMBO J.* 1999; 18 : 3990-4003.
50. Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. *Cancer Res.* 1997; 57 : 1429-34.
51. Loeb DM, Summers JL, Burwell EA, Korz D, Friedman AD, Sukumar S. An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. *Leukemia.* 2003; 17 : 965-71.
52. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. *Oncogene.* 2005; 24 : 1648-52.
53. Yamagami T, Ogawa H, Tamaki H, Oji Y, Soma T, Oka Y, *et al.* Suppression of Wilms' tumor gene (WT1) expression induces G2/M arrest in leukemic cells. *Leuk Res.* 1998; 22 : 383-4.

54. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. *Semin Oncol.* 1997; 24 : 103-13.
55. Blattner WA, Blayney DW, Robert-Guroff M, Sarngadharan MG, Kalyanaraman VS, Sarin PS, *et al.* Epidemiology of human T-cell leukemia/lymphoma virus. *J Infect Dis.* 1983; 147 : 406-16.
56. Chang KL, Weiss LM. The association of the Epstein-Barr virus with malignant lymphoma. *Biomed Pharmacother.* 1996; 50 : 459-67.
57. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* A variant form of hypergranular promyelocytic leukaemia (M3). *Br J Haematol.* 1980; 44 : 169-70.
58. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. *Ann Intern Med.* 1985; 103 : 620-5.
59. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). *Br J Haematol.* 1991; 78 : 325-9.
60. First MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of acute lymphoblastic leukemias. *Cancer Genetics and Cytogenetics.* 1986; 23 : 189-97.
61. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. *Cancer Genetics and Cytogenetics;* 1988; 30 : 1-15.

62. Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Second MIC Cooperative Study Group. *Br J Haematol.* 1988; 68 : 487-94.
63. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. *Int J Hematol.* 2000; 72 : 131-3.
64. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, *et al.* World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol.* 1999; 17 : 3835-49.
65. Harmening DM. Leukemia. *Clinical Hematology and Fundamentals of Hemostasis.* 4th ed.; 2002.
66. Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. *Blood.* 1987; 70 : 1400-6.
67. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, *et al.* Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. *Ann Intern Med.* 1985; 103 : 460-2.
68. Testa U, Torelli GF, Riccioni R, Muta AO, Mili S, Annino L, *et al.* Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. *Blood.* 2002; 99 : 4634-7.
69. Lichtman M. Leukemia. *William Hematology.* 7th ed.; 2005.

70. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuyneck H, Van Orshoven A, *et al.* Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. *Blood.* 1995; 85 : 3688-94.
71. Taj AS, Ross FM, Vickers M, Choudhury DN, Harvey JF, Barber JC, *et al.* t(8;21) myelodysplasia, an early presentation of M2 AML. *Br J Haematol.* 1995; 89 : 890-2.
72. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Associations between morphology, karyotype, and clinical features in myeloid leukemias. *Hum Pathol.* 1987; 18 : 211-25.
73. Hillestad LK. Acute promyelocytic leukemia. *Acta Med Scand.* 1957; 159 : 189-94.
74. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. *Hematology Am Soc Hematol Educ Program.* 2008 :3 91-9.
75. Tomonaga M, Yoshida Y, Tagawa M, Jinnai I, Kuriyama K, Amenomori T, *et al.* Cytochemistry of acute promyelocytic leukemia (M3): leukemic promyelocytes exhibit heterogeneous patterns in cellular differentiation. *Blood.* 1985; 66 : 350-7.
76. Willman CL. Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. *Mod Pathol.* 1999; 12 : 218-28.
77. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. *Blood.* 1983; 61 : 994-8.

78. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. *N Engl J Med.* 1983; 309 : 630-6.
79. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. *Blood.* 2003; 101 : 4301-4.
80. Hama A, Yagasaki H, Takahashi Y, Nishio N, Muramatsu H, Yoshida N, *et al.* Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. *Br J Haematol.* 2008; 140 : 552-61.
81. Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, *et al.* A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. *Blood.* 2007; 110 : 323-33.
82. Mercher T, Coniat MB, Monni R, Mauchauffe M, Nguyen Khac F, Gressin L, *et al.* Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. *Proc Natl Acad Sci U S A.* 2001; 98 : 5776-9.
83. Vartiainen MK, Guettler S, Larijani B, Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. *Science.* 2007; 316 : 1749-52.
84. Hitzler JK. Acute megakaryoblastic leukemia in Down syndrome. *Pediatr Blood Cancer.* 2007; 49 : 1066-9.
85. Lei Q, Liu Y, Tang SQ. Childhood acute megakaryoblastic leukemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 2007; 15 : 528-32.

86. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood*. 2002; 100 : 2292-302.
87. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. *Ann Intern Med*. 1999; 131 : 207-19.
88. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. *Hematology Am Soc Hematol Educ Program*. 2006 : 240-5.
89. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. *Lancet*. 2007; 370 : 342-50.
90. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. *Br J Haematol*. 1997; 96 : 111-6.
91. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, *et al*. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood*. 2007; 110 : 1092-7.
92. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med*. 2005; 352 : 804-15.
93. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, *et al*. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *J Exp Med*. 2001; 194 : 1639-47.

94. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, *et al.* The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. *Blood*. 2003; 101 : 1262-9.
95. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. *Ann Intern Med*. 2006; 145 : 435-47.
96. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, *et al.* Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med*. 2000; 343 : 1910-6.
97. Ascani S, Leoni P, Fraternali Orcioni G, Bearzi I, Piccioli M, Materazzi M, *et al.* T-cell prolymphocytic leukaemia: does the expression of CD8⁺ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. *Ann Oncol*. 1999; 10 : 649-53.
98. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. *Expert Rev Mol Med*. 2007; 9 : 1-17.
99. Rose EA, Glaser T, Jones C, Smith CL, Lewis WH, Call KM, *et al.* Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. *Cell*. 1990; 60 : 495-508.
100. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. *Proc Natl Acad Sci U S A*. 1991; 88 : 9618-22.
101. Scholz H, Kirschner KM. A role for the Wilms' tumor protein WT1 in organ development. *Physiology (Bethesda)*. 2005; 20 : 54-9.

102. Bruening W, Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. *J Biol Chem.* 1996; 271 : 8646-54.
103. Sharma PM, Bowman M, Madden SL, Rauscher FJ, 3rd, Sukumar S. RNA editing in the Wilms' tumor susceptibility gene, WT1. *Genes Dev.* 1994; 8 : 720-31.
104. Wang ZY, Qiu QQ, Deuel TF. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. *J Biol Chem.* 1993; 268 : 9172-5.
105. Scharnhorst V, Dekker P, van der Eb AJ, Jochemsen AG. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. *J Biol Chem.* 1999; 274 : 23456-62.
106. Wang ZY, Qiu QQ, Enger KT, Deuel TF. A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. *Proc Natl Acad Sci U S A.* 1993; 90 : 8896-900.
107. Caricasole A, Duarte A, Larsson SH, Hastie ND, Little M, Holmes G, *et al.* RNA binding by the Wilms tumor suppressor zinc finger proteins. *Proc Natl Acad Sci U S A.* 1996; 93 : 7562-6.
108. Kennedy D, Ramsdale T, Mattick J, Little M. An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling. *Nat Genet.* 1996; 12 : 329-31.
109. Huff V, Miwa H, Haber DA, Call KM, Housman D, Strong LC, *et al.* Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. *Am J Hum Genet.* 1991; 48 : 997-1003.

110. Tadokoro K, Fujii H, Ohshima A, Kakizawa Y, Shimizu K, Sakai A, *et al.* Intragenic homozygous deletion of the WT1 gene in Wilms' tumor. *Oncogene*. 1992; 7 : 1215-21.
111. Ton CC, Huff V, Call KM, Cohn S, Strong LC, Housman DE, *et al.* Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. *Genomics*. 1991; 10 : 293-7.
112. Algar EM, Kenney MT, Simms LA, Smith SI, Kida Y, Smith PJ. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript. *Hum Mutat*. 1995; 5 : 221-7.
113. Little MH, Prosser J, Condie A, Smith PJ, Van Heyningen V, Hastie ND. Zinc finger point mutations within the WT1 gene in Wilms tumor patients. *Proc Natl Acad Sci U S A*. 1992; 89 : 4791-5.
114. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, *et al.* Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. *Proc Natl Acad Sci U S A*. 1997; 94 : 3972-7.
115. Drummond IA, Rupprecht HD, Rohwer-Nutter P, Lopez-Guisa JM, Madden SL, Rauscher FJ, 3rd, *et al.* DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1. *Mol Cell Biol*. 1994; 14 : 3800-9.
116. Hewitt SM, Fraizer GC, Wu YJ, Rauscher FJ, 3rd, Saunders GF. Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation. *J Biol Chem*. 1996; 271 : 8588-92.

117. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ, 3rd. Transcriptional repression mediated by the WT1 Wilms tumor gene product. *Science*. 1991; 253 : 1550-3.
118. Rupprecht HD, Drummond IA, Madden SL, Rauscher FJ, 3rd, Sukhatme VP. The Wilms' tumor suppressor gene WT1 is negatively autoregulated. *J Biol Chem*. 1994; 269 : 6198-206.
119. Webster NJ, Kong Y, Sharma P, Haas M, Sukumar S, Seely BL. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter. *Biochem Mol Med*. 1997; 62 : 139-50.
120. Ladomery MR, Slight J, Mc Ghee S, Hastie ND. Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear poly(A)(+) ribonucleoprotein. *J Biol Chem*. 1999; 274 : 36520-6.
121. Algar E. A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia. *J Hematother Stem Cell Res*. 2002; 11 : 589-99.
122. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, *et al*. Induction of apoptosis in fibroblasts by c-myc protein. *Cell*. 1992; 69 : 119-28.
123. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? *Int Rev Cytol*. 1998; 181 : 151-212.
124. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. *Blood*. 2000; 96 : 1480-9.
125. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. *Blood*. 1996; 87 : 2171-9.

126. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y, *et al.* Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). *Leuk Res.* 1999; 23 : 499-505.
127. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. *EMBO J.* 2001; 20 : 1897-909.
128. Svedberg H, Richter J, Gullberg U. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. *Leukemia.* 2001; 15 : 1914-22.
129. Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34⁺ cells. *Exp Hematol.* 1998; 26 : 353-60.
130. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. *Blood.* 1998; 91 : 2961-8.
131. Shichishima T, Okamoto M, Ikeda K, Kaneshige T, Sugiyama H, Terasawa T, *et al.* HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. *Blood.* 2002; 100 : 22-8.
132. Farnworth NR BN. Thai Medicinal Plants, recommended for primary health care system. Medicinal Plant Information Center, Faculty of Pharmacy, Mahidol University, Sri-ayuthaya road, Bangkok, Thailand, Prachachon Co Ltd 402.
133. Daybe FV. Uber Curcumin. den Farbstoff der Curcumawurzzel Ber. 1870; 3 : 609.
134. Lampe MV. *J Ver Dtsch Chem Ges.* 1913; 46 : 2235.

135. Das Sa. 2008. "Curcuma longa Plant and chemical structure of curcumin, the active ingredient of rhizome turmeric". 2008. [online]. Available: <http://www.celldiv.com/content/download/figures/1747-1028-3-14-3.JPG> (18 November 2010).
136. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, *et al.* Stability of curcumin in buffer solutions and characterization of its degradation products. *J Pharm Biomed Anal.* 1997; 15 : 1867-76.
137. Jovanovic SV, Simic MG. Redox properties of oxy and antioxidant radicals. *Basic Life Sci.* 1988; 49 : 115-22.
138. Payton F, Sandusky P, Alworth WL. NMR study of the solution structure of curcumin. *J Nat Prod.* 2007; 70 : 143-6.
139. Lin JK, Liang YC. Cancer chemoprevention by tea polyphenols. *Proc Natl Sci Counc Repub China B.* 2000; 24 : 1-13.
140. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res.* 2003; 23 : 363-98.
141. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. *Cell Mol Life Sci.* 2008; 65 : 1631-52.
142. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. *Eur J Cancer.* 2005; 41 : 1955-68.
143. Mohammadi K, Thompson KH, Patrick BO, Storr T, Martins C, Polishchuk E, *et al.* Synthesis and characterization of dual function vanadyl, gallium and indium curcumin complexes for medicinal applications. *J Inorg Biochem.* 2005; 99 : 2217-25.

144. Thompson KH, Bohmerle K, Polishchuk E, Martins C, Toleikis P, Tse J, *et al.* Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone. *J Inorg Biochem.* 2004; 98 : 2063-70.
145. Sumanont Y, Murakami Y, Tohda M, Vajragupta O, Matsumoto K, Watanabe H. Evaluation of the nitric oxide radical scavenging activity of manganese complexes of curcumin and its derivative. *Biol Pharm Bull.* 2004; 27 : 170-3.
146. Vajragupta O, Boonchoong P, Berliner LJ. Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. *Free Radic Res.* 2004; 38 : 303-14.
147. Benassi R, Ferrari E, Grandi R, Lazzari S, Saladini M. Synthesis and characterization of new beta-diketo derivatives with iron chelating ability. *J Inorg Biochem.* 2007; 101 : 203-13.
148. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo MA, Gonzalez-Vergara E, Rojas-Hernandez A. Spectrophotometric and electrochemical determination of the formation constants of the complexes Curcumin-Fe(III)-water and Curcumin-Fe(II)-water. *Spectrochim Acta A Mol Biomol Spectrosc.* 2004; 60 : 1105-13.
149. Ahsan H, Hadi SM. Strand scission in DNA induced by curcumin in the presence of Cu(II). *Cancer Lett.* 1998; 124 : 23-30.
150. Barik A, Mishra B, Kunwar A, Kadam RM, Shen L, Dutta S, *et al.* Comparative study of copper(II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. *Eur J Med Chem.* 2007; 42 : 431-9.

151. Barik A, Mishra B, Shen L, Mohan H, Kadam RM, Dutta S, *et al.* Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. *Free Radic Biol Med.* 2005; 39 : 811-22.
152. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo M, Gonzalez-Vergara E, Rojas-Hernandez A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. *Spectrochim Acta A Mol Biomol Spectrosc.* 2004; 60 : 1091-7.
153. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. *Z Lebensm Unters Forsch.* 1985; 180 : 402-4.
154. Tonnesen HH, Karlsen J, van Henegouwen GB. Studies on curcumin and curcuminoids. VIII. Photochemical stability of curcumin. *Z Lebensm Unters Forsch.* 1986; 183 : 116-22.
155. Ammon HP, Wahl MA. Pharmacology of *Curcuma longa*. *Planta Med.* 1991; 57 : 1-7.
156. Ireson C, Orr S, Jones DJ, Verschoye R, Lim CK, Luo JL, *et al.* Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. *Cancer Res.* 2001; 61 : 1058-64.
157. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, *et al.* Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. *Cancer Epidemiol Biomarkers Prev.* 2002; 11 : 105-11.

158. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. *Xenobiotica*. 1978; 8 : 761-8.
159. Eigner D, Scholz D. Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. *J Ethnopharmacol*. 1999; 67 : 1-6.
160. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. *Cancer Lett*. 1995; 94 : 79-83.
161. Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. *J Pharm Pharmacol*. 1973; 25 : 447-52.
162. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. *Biochem Pharmacol*. 1996; 52 : 519-25.
163. Jordan WC, Drew CR. Curcumin--a natural herb with anti-HIV activity. *J Natl Med Assoc*. 1996; 88 : 333.
164. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. *Cancer Res*. 2003; 63 : 7291-300.
165. Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (*Curcuma longa*). *Cancer Lett*. 1985; 29 : 197-202.
166. Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (*Curcuma longa*) and curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. *Anticancer Res*. 2002; 22 : 4179-81.

167. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. *Biochem Biophys Res Commun.* 2005; 326 : 472-4.
168. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepatotoxic principles of *Curcuma longa* rhizomes. *Planta Med.* 1983; 49 : 185-7.
169. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. *Br J Pharmacol.* 1998; 124 : 425-7.
170. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. *Br J Pharmacol.* 2000; 129 : 231-4.
171. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. *Thromb Res.* 1985; 40 : 413-7.
172. Dikshit M, Rastogi L, Shukla R, Srimal RC. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. *Indian J Med Res.* 1995; 101 : 31-5.
173. Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. *Plant Foods Hum Nutr.* 2002; 57 : 41-52.
174. Babu PS, Srinivasan K. Hypolipidemic action of curcumin, the active principle of turmeric (*Curcuma longa*) in streptozotocin induced diabetic rats. *Mol Cell Biochem.* 1997; 166 : 169-75.
175. Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. *Indian J Med Sci.* 1972; 26 : 269-70.
176. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). *Indian J Med Res.* 1980; 71 : 632-4.

177. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, *et al.* Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res.* 2001; 21 : 2895-900.
178. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, *et al.* Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med.* 2006; 6 : 1-10.
179. Qureshi S, Shah AH, Ageel AM. Toxicity studies on *Alpinia galanga* and *Curcuma longa*. *Planta Med.* 1992; 58 : 124-7.
180. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (*Curcuma longa*): acute toxicity studies in rats, guineapigs & monkeys. *Indian J Exp Biol.* 1980; 18 : 73-5.
181. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med.* 1998; 64 : 353-6.
182. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. *Biochem Pharmacol.* 2007; 73 : 1024-32.
183. Hsu CH, Cheng AL. Clinical studies with curcumin. *Adv Exp Med Biol.* 2007; 595 : 471-80.
184. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. *Annu Rev Cell Biol.* 1994; 10 : 405-55.

185. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. *Annu Rev Immunol.* 1994; 12 : 141-79.
186. Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. *Int Rev Cytol.* 1993; 143 : 1-62.
187. Baeuerle PA. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. *Biochim Biophys Acta.* 1991; 1072 : 63-80.
188. Dhar A, Young MR, Colburn NH. The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. *Mol Cell Biochem.* 2002; 234-235 : 185-93.
189. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. *Nat Cell Biol.* 2002; 4 : E131-6.
190. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. *Free Radic Biol Med.* 2000; 28 : 1338-48.
191. Dong Z, Lavrovsky V, Colburn NH. Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. *Carcinogenesis.* 1995; 16 : 749-56.
192. Xu YX, Pindolia KR, Janakiraman N, Noth CJ, Chapman RA, Gautam SC. Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. *Exp Hematol.* 1997; 25 : 413-22.

193. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. *Matrix Biol.* 2002; 21 : 251-62.
194. Hanazawa S, Takeshita A, Amano S, Semba T, Nirazuka T, Katoh H, et al. Tumor necrosis factor-alpha induces expression of monocyte chemoattractant JE via fos and jun genes in clonal osteoblastic MC3T3-E1 cells. *J Biol Chem.* 1993; 268 : 9526-32.
195. Chen YR, Zhou G, Tan TH. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. *Mol Pharmacol.* 1999; 56 : 1271-9.
196. Hahm ER, Cheon G, Lee J, Kim B, Park C, Yang CH. New and known symmetrical curcumin derivatives inhibit the formation of Fos-Jun-DNA complex. *Cancer Lett.* 2002; 184 : 89-96.
197. Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. *FEBS Lett.* 1994; 341 : 19-22.
198. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. *Carcinogenesis.* 1993; 14 : 857-61.
199. Hasmeda M, Polya GM. Inhibition of cyclic AMP-dependent protein kinase by curcumin. *Phytochemistry.* 1996; 42 : 599-605.
200. Pendurthi UR, Rao LV. Suppression of transcription factor Egr-1 by curcumin. *Thromb Res.* 2000; 97 : 179-89.

201. Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. *Biochim Biophys Acta*. 1994; 1224 : 597-600.
202. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. *Carcinogenesis*. 1995; 16 : 1741-5.
203. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. *Mol Urol*. 2000; 4 : 1-6.
204. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. *Clin Cancer Res*. 1999; 5 : 1884-91.
205. Liu Y, Chang RL, Cui XX, Newmark HL, Conney AH. Synergistic effects of curcumin on all-trans retinoic acid- and 1 alpha,25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukemia HL-60 cells. *Oncol Res*. 1997; 9 : 19-29.
206. Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. *J Agric Food Chem*. 2001; 49 : 1464-74.
207. Roy M, Chakraborty S, Siddiqi M, Bhattacharya RK. Induction of Apoptosis in Tumor Cells by Natural Phenolic Compounds. *Asian Pac J Cancer Prev*. 2002; 3 : 61-7.

208. Sokoloski JA, Hodnick WF, Mayne ST, Cinquina C, Kim CS, Sartorelli AC. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. *Leukemia*. 1997; 11 : 1546-53.
209. Bielak-Mijewska A, Piwocka K, Magalska A, Sikora E. P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells. *Cancer Chemother Pharmacol*. 2004; 53 : 179-85.
210. Chen Y, Wu Y, He J, Chen W. The experimental and clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia. *J Huazhong Univ Sci Technolog Med Sci*. 2002; 22 : 295-8.
211. Atsumi T, Murakami Y, Shibuya K, Tonosaki K, Fujisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. *Anticancer Res*. 2005; 25 : 4029-36.
212. Chen J, Wanming D, Zhang D, Liu Q, Kang J. Water-soluble antioxidants improve the antioxidant and anticancer activity of low concentrations of curcumin in human leukemia cells. *Pharmazie*. 2005; 60 : 57-61.
213. Tan TW, Tsai HR, Lu HF, Lin HL, Tsou MF, Lin YT, *et al*. Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation. *Anticancer Res*. 2006; 26 : 4361-71.

214. Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. *Basic Clin Pharmacol Toxicol.* 2007; 101 : 427-33.
215. Liu HL, Chen Y, Cui GH, Zhou JF. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. *Acta Pharmacol Sin.* 2005; 26 : 603-9.
216. Sun CY, Liu XY, Chen Y, Liu F, Wang Y. Experimental study on anticancer effect of curcumin on Raji cells in vitro. *Zhongguo Zhong Xi Yi Jie He Za Zhi.* 2004; 24 : 1003-6.
217. Wu Q, Chen Y, Li X. HDAC1 expression and effect of curcumin on proliferation of Raji cells. *J Huazhong Univ Sci Technolog Med Sci.* 2006; 26 : 199-210.
218. Blasius R, Reuter S, Henry E, Dicato M, Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. *Biochem Pharmacol.* 2006; 72 : 1547-54.
219. Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. *Mutat Res.* 2006; 596 : 81-90.
220. Singhal SS, Awasthi S, Pandya U, Piper JT, Saini MK, Cheng JZ, *et al.* The effect of curcumin on glutathione-linked enzymes in K562 human leukemia cells. *Toxicol Lett.* 1999; 109 : 87-95.

221. Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ. Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. *Biochem Biophys Res Commun.* 2006; 340 : 359-68.
222. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, *et al.* Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. *Int J Cancer.* 2006; 118 : 765-72.
223. Chen WH, Chen Y, Cui GH, Gu JX, Hu D, Chen WK, *et al.* Effect of curcumin on STAT5 signaling pathway in primary CML cells. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 2004; 12 : 572-6.
224. Jiang DZ, Xie QY, Wang QR. Effect of curcumin on the proliferation of murine CFU-GM and WEHI-3B cells. *Hunan Yi Ke Da Xue Xue Bao.* 2000; 25 : 216-8.
225. Martin-Cordero C, Lopez-Lazaro M, Galvez M, Ayuso MJ. Curcumin as a DNA topoisomerase II poison. *J Enzyme Inhib Med Chem.* 2003; 18 : 505-9.
226. Kellner C, Zunino SJ. Nitric oxide is synthesized in acute leukemia cells after exposure to phenolic antioxidants and initially protects against mitochondrial membrane depolarization. *Cancer Lett.* 2004; 215 : 43-52.
227. Bhaumik S, Jyothi MD, Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. *FEBS Lett.* 2000; 483 : 78-82.

228. Piwocka K, Jaruga E, Skierski J, Gradzka I, Sikora E. Effect of glutathione depletion on caspase-3 independent apoptosis pathway induced by curcumin in Jurkat cells. *Free Radic Biol Med.* 2001; 31 : 670-8.
229. Sikora E, Bielak-Zmijewska A, Magalska A, Piwocka K, Mosieniak G, Kalinowska M, et al. Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. *Mol Cancer Ther.* 2006; 5 : 927-34.
230. Wolanin K, Magalska A, Mosieniak G, Klinger R, McKenna S, Vejda S, et al. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. *Mol Cancer Res.* 2006; 4 : 457-69.
231. Aggarwal BB. Nuclear factor-kappa B: a transcription factor for all seasons. *Expert Opin Ther Targets.* 2007; 11 : 109-10.
232. Zambre AP, Kulkarni VM, Padhye S, Sandur SK, Aggarwal BB. Novel curcumin analogs targeting TNF-induced NF-kappaB activation and proliferation in human leukemic KBM-5 cells. *Bioorg Med Chem.* 2006; 14 : 7196-204.
233. Polasa K, Naidu AN, Ravindranath I, Krishnaswamy K. Inhibition of B(a)P induced strand breaks in presence of curcumin. *Mutat Res.* 2004; 557 : 203-13.
234. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, et al. Efficacy of curcumin in the management of chronic anterior uveitis. *Phytother Res.* 1999; 13 : 318-22.

235. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. *Phytother Res.* 2000; 14 : 443-7.
236. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. *Int J Clin Pharmacol Ther Toxicol.* 1986; 24 : 651-4.
237. Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. *Tumori.* 1987; 73 : 29-31.
238. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, *et al.* Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin Cancer Res.* 2004; 10 : 6847-54.
239. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, *et al.* Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. *Clin Cancer Res.* 2001; 7 : 1894-900.
240. Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. *Cancer Epidemiol Biomarkers Prev.* 2001; 10 : 1295-9.
241. Tohda C, Nakayama N, Hatanaka F, Komatsu K. Comparison of Anti-inflammatory Activities of Six Curcuma Rhizomes: A Possible Curcuminoid-independent Pathway Mediated by Curcuma phaeocaulis Extract. *Evid Based Complement Alternat Med.* 2006; 3 : 255-60.
242. Tayyem RF, Heath DD, Al-Delaimy WK, Rock CL. Curcumin content of turmeric and curry powders. *Nutr Cancer.* 2006; 55 : 126-31.

243. Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Improved HPLC method for the determination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. *J Agric Food Chem.* 2002; 50 : 3668-72.
244. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from *Curcuma longa*. *Phytomedicine.* 2000; 7 : 303-8.
245. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, *et al.* Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. *Br J Cancer.* 2004; 90 : 1011-5.
246. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. *Acta Pharmacol Toxicol (Copenh).* 1978; 43 : 86-92.
247. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. *Toxicology.* 1980; 16 : 259-65.
248. Ravindranath V, Chandrasekhara N. Metabolism of curcumin-studies with [³H]curcumin. *Toxicology.* 1981; 22 : 337-44.
249. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. *Toxicology.* 1981; 20 : 251-7.
250. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab Dispos.* 1999; 27 : 486-94.
251. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007; 4 : 807-18.

252. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, *et al.* Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. *Clin Cancer Res.* 2001; 7 : 1452-8.
253. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. *Indian J Physiol Pharmacol.* 1992; 36 : 273-5.
254. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. *Biochem Pharmacol.* 2004; 68 : 2043-52.
255. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. *BMC Cancer.* 2004; 4 : 13.
256. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods.* 1983; 65 : 55-63.
257. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. *Biotechnology (N Y).* 1993; 11 : 1026-30.
258. Harris NL. Always sanitary napkins: further reports and manufacturer response. *CMAJ.* 1996; 155 : 1035; author reply 6.
259. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. *Biotechniques.* 1998; 24 : 954-62.

260. Wang T, Brown MJ. mRNA quantification by real time TaqMan polymerase chain reaction: validation and comparison with RNase protection. *Anal Biochem.* 1999; 269 : 198-201.
261. Malinen E, Kassinen A, Rinttila T, Palva A. Comparison of real-time PCR with SYBR Green I or 5'-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected faecal bacteria. *Microbiology.* 2003; 149 : 269-77.
262. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, *et al.* New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J Clin Microbiol.* 2003; 41 : 4531-6.
263. Gentle A, Anastasopoulos F, McBrien NA. High-resolution semi-quantitative real-time PCR without the use of a standard curve. *Biotechniques.* 2001; 31 : 502-8.
264. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. *Anal Biochem.* 2000; 285 : 194-204.
265. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. *Exp Hematol.* 2002; 30 : 503-12.
266. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem.* 1951; 193 : 265-75.
267. Peterson GL. Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. *Anal Biochem.* 1979; 100 : 201-20.

268. Kaufmann SH, Ewing CM, Shaper JH. The erasable Western blot. *Anal Biochem.* 1987; 161 : 89-95.
269. Collas P. The current state of chromatin immunoprecipitation. *Mol Biotechnol.* 2010; 45 : 87-100.
270. Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V, et al. Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. *J Biol Chem.* 1994; 269 : 8892-900.
271. Wikipedia the free Encyclopedia. Signaling transduction. [online]. Available: http://en.wikipedia.org/wiki/Signal_transduction (5 January 2011)
272. Furuhashi A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S, et al. GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. *Leukemia.* 2009; 23 : 1270-7.
273. Jensen ON. Interpreting the protein language using proteomics. *Nat Rev Mol Cell Biol.* 2006; 7 : 391-403.
274. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. *Cancer Lett.* 2008; 267 : 133-64.
275. Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. *Free Radic Biol Med.* 2000; 28 : 1349-61.
276. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. *Cancer Lett.* 2008; 269 : 199-225.

277. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. *J Cell Biochem.* 2007; 102 : 580-92.
278. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. *Biochem Pharmacol.* 2008; 75 : 787-809.
279. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). *J Biol Chem.* 1995; 270 : 24995-5000.
280. Ye Y, Raychaudhuri B, Gurney A, Campbell CE, Williams BR. Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. *EMBO J.* 1996; 15 : 5606-15.
281. Svedberg H, Chylicki K, Baldetorp B, Rauscher FJ, 3rd, Gullberg U. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. *Oncogene.* 1998; 16 : 925-32.
282. Lin JK. Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by Curcumin. *Arch Pharm Res.* 2004; 27 : 683-92.
283. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? *AAPS J.* 2009; 11 : 495-510.
284. Wan SB, Yang H, Zhou Z, Cui QC, Chen D, Kanwar J, *et al.* Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. *Int J Mol Med.* 2010; 26 : 447-55.

285. Majhi A, Rahman GM, Panchal S, Das J. Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C. *Bioorg Med Chem*. 2010; 18 : 1591-8.
286. Lopez-Bergami P, Ronai Z. Requirements for PKC-augmented JNK activation by MKK4/7. *Int J Biochem Cell Biol*. 2008; 40 : 1055-64.
287. Chow JM, Shen SC, Wu CY, Chen YC. 12-o-Tetradecanoylphorbol 13-acetate prevents baicalein-induced apoptosis via activation of protein kinase C and JNKs in human leukemia cells. *Apoptosis*. 2006; 11 : 1999-2011.
288. Zhang H, Forman HJ. Acrolein induces heme oxygenase-1 through PKC-delta and PI3K in human bronchial epithelial cells. *Am J Respir Cell Mol Biol*. 2008; 38 : 483-90.
289. Ng T, Shima D, Squire A, Bastiaens PI, Gschmeissner S, Humphries MJ, et al. PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. *EMBO J*. 1999; 18 : 3909-23.
290. Yamboliev IA, Mutafova-Yambolieva VN. PI3K and PKC contribute to membrane depolarization mediated by alpha2-adrenoceptors in the canine isolated mesenteric vein. *BMC Physiol*. 2005; 5 : 1-9.
291. Leitges M, Plomann M, Standaert ML, Bandyopadhyay G, Sajan MP, Kanoh Y, et al. Knockout of PKC alpha enhances insulin signaling through PI3K. *Mol Endocrinol*. 2002; 16 : 847-58.
292. Standaert ML, Bandyopadhyay G, Kanoh Y, Sajan MP, Farese RV. Insulin and PIP3 activate PKC-zeta by mechanisms that are both dependent and independent of phosphorylation of activation loop (T410) and autophosphorylation (T560) sites. *Biochemistry*. 2001; 40 : 249-55.

293. Aoyama E, Yoshihara R, Tai A, Yamamoto I, Gohda E. PKC- and PI3K-dependent but ERK-independent proliferation of murine splenic B cells stimulated by chondroitin sulfate B. *Immunol Lett.* 2005; 99 : 80-4.
294. Vargas-Roig LM, Fanelli MA, Lopez LA, Gago FE, Tello O, Aznar JC, et al. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. *Cancer Detect Prev.* 1997; 21 : 441-51.
295. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. *Proteomics.* 2003; 3 : 433-9.
296. Regazzi R, Eppenberger U, Fabbro D. The 27,000 daltons stress proteins are phosphorylated by protein kinase C during the tumor promoter-mediated growth inhibition of human mammary carcinoma cells. *Biochem Biophys Res Commun.* 1988; 152 : 62-8.
297. Strahler JR, Kuick R, Eckerskorn C, Lottspeich F, Richardson BC, Fox DA, et al. Identification of two related markers for common acute lymphoblastic leukemia as heat shock proteins. *J Clin Invest.* 1990; 85 : 200-7.
298. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. *Mol Cell Biol.* 1991; 11 : 1707-12.
299. Madden SL, Rauscher FJ, 3rd. Positive and negative regulation of transcription and cell growth mediated by the EGR family of zinc-finger gene products. *Ann NY Acad Sci.* 1993; 684 : 75-84.

300. Joseph LJ, Le Beau MM, Jamieson GA, Jr., Acharya S, Shows TB, Rowley JD, *et al.* Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure. *Proc Natl Acad Sci U S A.* 1988; 85 : 7164-8.
301. Muller HJ, Skerka C, Bialonski A, Zipfel PF. Clone pAT 133 identifies a gene that encodes another human member of a class of growth factor-induced genes with almost identical zinc-finger domains. *Proc Natl Acad Sci U S A.* 1991; 88 : 10079-83.
302. Rangnekar VM, Aplin AC, Sukhatme VP. The serum and TPA responsive promoter and intron-exon structure of EGR2, a human early growth response gene encoding a zinc finger protein. *Nucleic Acids Res.* 1990; 18 : 2749-57.
303. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC, *et al.* A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. *Cell.* 1988; 53 : 37-43.
304. Patwardhan S, Gashler A, Siegel MG, Chang LC, Joseph LJ, Shows TB, *et al.* EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. *Oncogene.* 1991; 6 : 917-28.
305. Bickmore WA, Oghene K, Little MH, Seawright A, van Heyningen V, Hastie ND. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. *Science.* 1992; 257 : 235-7.
306. Wu Y, Fraizer GC, Saunders GF. GATA-1 transactivates the WT1 hematopoietic specific enhancer. *J Biol Chem.* 1995; 270 : 5944-9.
307. Cohen HT, Bossone SA, Zhu G, McDonald GA, Sukhatme VP. Sp1 is a critical regulator of the Wilms' tumor-1 gene. *J Biol Chem.* 1997; 272 : 2901-13.

308. Sciesielski LK, Kirschner KM, Scholz H, Persson AB. Wilms' tumor protein Wt1 regulates the Interleukin-10 (IL-10) gene. *FEBS Lett.* 2010 ; 584 : 4665-71.
309. Vidovic K, Svensson E, Nilsson B, Thuresson B, Olofsson T, Lennartsson A, *et al.* Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. *Leukemia.* 2010; 24 : 992-1000.
310. Hannoun Z, Greenhough S, Jaffray E, Hay RT, Hay DC. Post-translational modification by SUMO. *Toxicology.* 2010; 278 : 288-93.
311. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. *J Biol Chem.* 1997;272 : 24735-8.